Donna McMorrow
YOU?
Author Swipe
View article: Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis
Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis Open
Patients treated with mepolizumab demonstrated progressive and sustained long-term, real-world reductions in exacerbation frequency, OCS dependency, and exacerbation-related HCRU and costs over 4 years.
View article: Cost of early progression: patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer
Cost of early progression: patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer Open
Aim: Compare healthcare costs for patients with epidermal growth factor receptor mutated (EGFRm) metastatic non-small-cell lung cancer (mNSCLC) with and without progression and estimate costs of progression.Materials & methods: Retrospecti…
View article: Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors
Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors Open
Background: Long-acting somatostatin analog therapy (LA-SSA) is recommended as first-line therapy for treatment of unresectable or metastatic neuroendocrine tumors (NETs). Understanding treatment sequencing and dosing patterns of LA-SSA is…
View article: Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors
Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors Open
Background Long-acting somatostatin analog therapy (LA-SSA) is recommended as first-line therapy for treatment of unresectable or metastatic neuroendocrine tumors (NETs). Understanding treatment sequencing and dosing patterns of LA-SSA is …
View article: Changes in Oral Corticosteroid Utilization in Patients with COPD Following Initiation of FF/UMEC/VI
Changes in Oral Corticosteroid Utilization in Patients with COPD Following Initiation of FF/UMEC/VI Open
Among patients with COPD with prior OCS use, FF/UMEC/VI initiation resulted in significant reductions in OCS utilization, COPD-related HCRU (including hospitalization), and all-cause HCRU.
View article: Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States
Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States Open
Background/Objective Although the high disease burden associated with eosinophilic granulomatosis with polyangiitis (EGPA) has been established, the disease burden in patients initiating mepolizumab in real-world practice is poorly underst…
View article: Work Loss and Direct and Indirect Costs Associated with Parkinson’s Disease
Work Loss and Direct and Indirect Costs Associated with Parkinson’s Disease Open
PD has both a significant direct and indirect financial burden on patients and their spouses when analyzed for 3 years before and after diagnosis.
View article: Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma
Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma Open
Treatment patterns among patients with relapsed or refractory LBCL eligible for SCT were highly varied. Only 22.7% of patients who received an SCT-preparative regimen ultimately received SCT, which highlights the magnitude of unmet needs i…
View article: Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis
Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis Open
These data from patients with life-threatening asthma in clinical practice demonstrated that asthma exacerbation and OCS use were significantly reduced with mepolizumab treatment.
View article: A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumab
A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumab Open
In patients with SEA on high-dose ICS, a reduction in both ICS and OCS use was observed after initiating mepolizumab. These findings have important implications for clinical outcomes and follow-up care in this patient population.
View article: Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities
Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities Open
Mepolizumab treatment provided real-world clinical benefits in patients.
View article: <p>Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma</p>
Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma Open
Our findings demonstrate that mepolizumab therapy is associated with reduced OCS use in patients treated in a real-world setting, potentially mitigating adverse health sequelae caused by OCS use in these patients.
View article: Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data
Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data Open
This study was sponsored by Amgen. Amgen employees contributed to study design, analysis of the data, and the decision to publish the results. Maksabedian Hernandez and Stolshek are employees and shareholders of Amgen; Gharaibeh was employ…
View article: Evaluation of the accuracy of algorithms to identify soft tissue sarcoma (STS) in administrative claims
Evaluation of the accuracy of algorithms to identify soft tissue sarcoma (STS) in administrative claims Open
Background Lack of using a validated algorithm to select patients is a source of selection bias in oncology studies using administrative claims. The objective of this study to evaluate published algorithms to identify patients with soft ti…
View article: Association Between Switching to a High-Deductible Health Plan and Discontinuation of Type 2 Diabetes Treatment
Association Between Switching to a High-Deductible Health Plan and Discontinuation of Type 2 Diabetes Treatment Open
These findings suggest switching to an HDHP is associated with discontinuation specifically of branded medications. Unintended health consequences may result and should be considered by employers making health care benefit decisions.
View article: <p>Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis</p>
Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis Open
Purpose: To describe health care resource utilization (HCRU) and costs among patients with juvenile idiopathic arthritis (JIA) compared to patients without JIA and to describe treatment patterns among JIA patients who initiated biologic an…
View article: Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy.
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy. Open
Among patients with RA, patients who switched from a TNF inhibitor to an alternative MOA agent and those who cycled between alternative MOA agents had significantly higher treatment persistence rates and a substantially lower cost per pers…
View article: Real-World Economic Burden Associated with Transplantation-Related Complications
Real-World Economic Burden Associated with Transplantation-Related Complications Open
Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are performed annually in the United States. Real-world data on the costs associated with post-transplantation complications are limited. Patients with hematologic ma…
View article: Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication
Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication Open
Although the absolute differences were small, these results support switching to a non-TNFi targeted DMARD instead of TNFi cycling when patients with RA require another therapy after TNFi failure.
View article: Association Between Weight Change, Clinical Outcomes, and Health Care Costs in Patients with Type 2 Diabetes
Association Between Weight Change, Clinical Outcomes, and Health Care Costs in Patients with Type 2 Diabetes Open
This study was sponsored by AstraZeneca and Bristol-Myers Squibb. Truven Health Analytics received funding from Bristol-Myers Squibb and AstraZeneca to conduct this study. Mukherjee is an employee of Bristol-Myers Squibb. Bell and Sternhuf…
View article: Transitions of Care for People with Type 2 Diabetes: Utilization of Antihyperglycemic Agents Pre- and Post-Hospitalization
Transitions of Care for People with Type 2 Diabetes: Utilization of Antihyperglycemic Agents Pre- and Post-Hospitalization Open
Janssen Scientific Affairs, LLC.
View article: Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic
Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic Open
Among RA patients treated with infused biologics after previously using at least one other biologic, patients treated with tocilizumab had the lowest real-world healthcare costs, largely driven by lower costs directly related to biologic t…